Viewing 0 reply threads
  • Author
    Posts
    • #12643
      Dagmar Munn
      Keymaster

      Masitinib in combination with Rilutek (riluzole) slows functional decline of patients with amyotrophic lateral sclerosis (ALS) who have a typical disease progression, according to the final report of AB Science‘s Phase 2/3 clinical trial.

      At 11 months of treatment with the combo, the rate of disability progression was reduced by 27%, as compared to a placebo plus Rilutek. In contrast, patients who have a faster disease worsening do not benefit as much from adding masitinib to their treatment.

      AB Science is now setting up a Phase 3 trial to confirm the latest results and gather more data in support of a new marketing application to the European Medicine Agency (EMA). Here is a link to their clinical trial planned to begin in November, 2019.
      Would you consider participating? What are your thoughts about Masitinib?
Viewing 0 reply threads
  • You must be logged in to reply to this topic.

©2021 KLEO Template a premium and multipurpose theme from Seventh Queen

CONTACT US

We're not around right now. But you can send us an email and we'll get back to you, asap.

Sending

Log in with your credentials

or    

Forgot your details?

Create Account